Clinical Efficacy of Dexamethasone in the Treatment of Patients with Tuberculous Meningitis: A Meta-Analysis

Table 1

Basic characteristics of the included studies.

Study	Year	Sample time (year.month)	Cases (Treat/Con)	Age (years)		Sex (male/female)		Measures (Con group)	Study design	Outcome measures
				Treat group	Treat group	Treat group	Con group
Huang Yuanzhi	2019	2018.01–2019.01	40/40	48.5 ± 3.3	48.5 ± 3.3	21/19	22/18	Isoniazid, rifampin, ethambutol, pyrazinamide	RCT	①③④⑤⑥
Liu Fang	2018	2014.01–2016.01	23/23	57.7 ± 2.4	57.9 ± 2.4	12/11	13/10	Isoniazid, rifampin, ethambutol, pyrazinamide	Retrospective	①③④⑤⑥
Liu Jie	2018	2016.08–2017.08	38/38	20–78	21–78	21/17	22/16	Isoniazid, rifampin, ethambutol, pyrazinamide	RCT	①③④⑤⑥
Li Lintao	2016	2015.05–2016.04	43/43	43.4 ± 1.8	42.1 ± 1.6	23/20	21/22	Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol	RCT	①②③④⑤⑥
Li Yingmin	2021	2018.02–2020.06	34/34	40.8 ± 4.3	40.1 ± 4.2	19/15	18/16	Isoniazid, rifampin, ethambutol, pyrazinamide	RCT	③④⑤⑥
Fan Xiu Li	2016	2014.07–2015.10	53/53	48.2 ± 3.3	48.0 ± 3.7	30/23	29/24	Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol	RCT	①②
Yang Fuyun	2018	NP	42/42	33.9 ± 4.3	34.8 ± 4.1	22/20	25/17	Isoniazid, rifampin, levofloxacin	NP	①③④⑤⑥
Lin Pingli	2015	2014.02–2015.01	48/48	40.1 ± 4.6	40.4 ± 4.1	20/28	21/27	Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol	RCT	①②③④⑤⑥
Guy E. Thwaites	2004	2001.04–2003.03	274/271	15–88	15–84	168/106	163/108	Isoniazid, rifampin, pyrazinamide, placebo	RCT	①②
H. S. Malhotra	2009	2006.01–2007.07	31/30	15–66	15–70	15/16	14/16	Isoniazid, rifampin, ethambutol, pyrazinamide, placebo	Retrospective	①②
Justin A. Green	2009	2001.04–2003.03	18/19	19.3–40.5	23.0–44.0	8/10	7/12	Isoniazid, rifampin, pyrazinamide, streptomycin, placebo	Retrospective	①②

Treat, treatment; Con, control; RCT, randomized controlled trial; NR, not reported; ①, effective rate; ②, adverse effects rate; ③, comparison of cerebrospinal fluid cell count after treatment; ④, comparison of protein content in cerebrospinal fluid after treatment; ⑤, comparison of glucose levels in cerebrospinal fluid after treatment; ⑥, comparison of chloride levels after treatment.